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Abstract 
Although statins, the most widely used drugs in the treatment of hyperlipidaemia, are 
generally accepted as efficient and safe drugs their side-effects on skeletal muscle have been 
reported with increasing frequency in the past years. The lack of an appropriate animal model 
in which these side effects would consistently be observed is one of the most important 
drawbacks in studying statin associated myopathy. To overcome this and enable the studying 
of the effects of fluvastatin on skeletal muscles an animal model with high blood cholesterol 
levels was developed. In these animals cholesterol levels rose more than seven fold (from 
1.5±0.1 to 10.7±2.0 mmol/L; n=15 and 16) with a dramatic increase in LDL/HDL ratio (from 
0.29±0.02 to 1.56±0.17). While the latter was reversed by statin treatment, an elevation in 
blood creatine kinase level indicated the presence of muscle wasting. Fibers from m. extensor 
digitorum longus (EDL) showed significant reduction in cross sectional area in the statin 
treated groups. Statin treatment also decreased the proliferation and fusion of skeletal 
myotubes in culture. In line with this, resting intracellular calcium concentration ([Ca2+]i) was 
reduced in statin treated satellite cells and myotubes. On the other hand, in adult skeletal 
muscle fibers statin treatment increased resting [Ca2+]i (116±4 vs. 151±5 nM; n= 33 and 34) 
and decreased both twitch and tetanic force both in EDL and m. soleus. In addition, in m. 
soleus the duration of twitch and tetanic force was shortened. These results clearly indicate 
that statin administration in these animals results in a myopathy characterized by decreased 
muscle force and elevated plasma creatine kinase level. 
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Introduction 
High blood cholesterol level, obesity and atherosclerosis are major health problems. 
They promote cardiovascular disorders as coronary sclerosis, myocardial ischemia or 
infarction and stroke. An effective way to decrease the associated morbidity and mortality is 
to treat the high blood cholesterol level with changes in lifestyle and if that is not sufficient 
enough, with medications (Merz et al. 2009) 
Statins are the most widespread and effective drugs lowering cholesterol levels, 
claimed to have a number of synergetic effects (Wang et al. 2008). They not only decrease the 
low density lipoprotein (LDL) and increase the high density lipoprotein (HDL) levels in the 
blood, but decrease the mortality of cardiovascular diseases (Ward et al. 2007). As of today, 
about 1.5 million patients’ lives were saved by the statin therapy all over the world (Pados 
and Audikovszky 2007). 
The cholesterol lowering effect of statins is exerted by the blockage of the hydroxy-
methyl-glutaryl-coenzyme-A (HMG-CoA) enzyme thus decreasing the endogenous 
cholesterol synthesis through the mevalonate pathway (Marcoff and Thompson 2007). This 
not only decreases the cholesterol production, but the farnesyl pyrophosphate and geranyl-
geranyl pyrophosphate levels are also lowered, thus the prenylation of proteins is blocked. 
Although statins have a lot of beneficial effects, the one year adherence to statin 
therapy in the USA is less than 50 % (Buettner and Lecker 2008). The main side effect which 
causes to cease the statin therapy is myopathy: muscle pain, cramps, and weakness, which 
affects mainly symmetrically the proximal muscles. These complications were observed in 
10.5% of the statin-treated patients, (Bruckert et al. 2005) and claimed to be present for all 
statins and dose dependent (Thompson et al. 2006). Importantly though blood creatine kinase 
(CK) level can increase, even independently of muscle complaints. The most feared side 
effect is, therefore, the fatal rhabdomyolysis characterized by a more than 10 fold increase in 
  4
blood CK level, elevated blood creatinin level and renal failure caused by myoglobinuria 
(Thompson et al. 2006). 
Although the pathomechanism of the statin associated myopathy has been studied in 
detail and several theories do exist, there is still no real consensus (Buettner and Lecker 
2008). The currently prevailing ideas include genetic predisposig factors, mitochondial 
dysfuction, lack of prenylated proteins and coenzyme Q10, altered cell membrane function 
and altered calcium homeostasis. One of the major drawbacks for a detailed investigation of 
the pathomechanism was the lack of an appropriate model system, an animal model in which 
statin treatment would cause distinct muscle weakness in most of the treated animals not only 
in one of every several thousand (or million, as in the average human population). 
Here we report of an animal model in which increased blood cholesterol levels are 
present and upon chronic statin treatment muscle degeneration develops in essentially every 
animal thus enabling the study of statin-induced myopathy. These animals were weaker, 
showing the pathological effects of statins, including increased blood creatine kinase levels, 
observed on affected humans. This weakness manifested as a decrease in both twitch and 
tetanic force of the muscles examined. Together with these alterations the resting intracellular 
calcium concentration of the fibers was also modified. 
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Methods 
 
Animal models 
Animals were housed in accordance with the guidelines and the approved protocol of 
the Animal Care Committee of the University of Debrecen. Female Fischer rats were fed with 
different pre-mixed chows from Charles River Laboratories for at least 21 days, and were 
allowed to consume the food and tap water ad libitum. The control (C) group was fed with 
standard rodent chow. For the statin (S) group this standard rodent chow was mixed with 
6.4 mg/kg/day fluvastatin. The group with high blood cholesterol (hypercholesterolaemic; 
HC) was fed with high, 5 g/kg/day cholesterol containing chow, in addition with 1 g/kg/day 
cholic acid, which facilitates the absorption of cholesterol in the rat small intestine, and 
1 g/kg/day thiouracil, which provided us an additional rise in the blood cholesterol level. The 
hypercholesterolaemic and statin treated (HC+S) group was kept on high cholesterol and 
fluvastatin containing diet at the above mentioned concentrations. We set up a second control 
group, the thiouracil (TU) group, in which the diet contained the same dose of thiouracil as 
mentioned above, mixed with the standard rodent chow, in order to exclude the effect of 
hypothyroidism on skeletal muscles. The animals’ weights were measured daily together with 
the daily food intake. 
Animals were anaesthetized and sacrificed following a protocol approved by the 
Animal Care Committee of the University of Debrecen. After pentobarbithal anesthesia 
(27 mg/kg), the m. extensor digitorum communis (EDC) from the fore limb, and m. extensor 
digitorum longus (EDL) and m. soleus (Sol) were dissected from the hind limb. Then the 
abdomen was opened and the abdominal Aorta plunged in order to collect blood samples. 
Finally the heart was also removed from the animal. 
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Some animals were anesthetized with the same dose of pentobarbital, and after 
collecting the blood from the abdominal Aorta the bodies were used for pathological 
examination. 
 
Striated muscle cell culture 
Primary striated muscle cell culture was established from 3-7 days old Wistar rats. The 
animals were sacrificed in accordance with the guidelines and the approved protocol of the 
Animal Care Committee of the University of Debrecen with a slight modification of a method 
described in detail elsewhere (Cseri et al. 2002). In brief, the m. quadriceps femoris, m. 
soleus, and m. gastrocnaemius were removed, enzymatically digested in a calcium and 
magnesium free phosphate buffer with 0.75 mg/ml type 2 collagenase (Sigma, St. Louis, Mo., 
USA) and trypsin (Difco, Detroit, Mich., USA). Dissociated cells were seeded on glass 
coverslips in HAM’s F12 growth medium (Sigma) containing 15% fetal bovine serum, and 
were kept at 37°C in a 5% CO2 containing atmosphere. After 24 hours, two different groups 
were separated. Control cells were placed in a differentiating medium (DMEM; Sigma) with 
5% Horse serum. The cells in the statin group were placed in the same differentiating medium 
containing 10 nM fluvastatin. 
 
Blood sample analysis 
The blood cholesterol level of the rats was evaluated to prove the efficacy of the high 
cholesterol containing diets. We measured the total cholesterol level, the LDL and the HDL 
cholesterol levels and the triglyceride level. To evaluate the extent of the myopathy the blood 
CK level was also measured. These tests were performed in the Department of Clinical 
Biochemistry and Molecular Pathology of the University of Debrecen with their standardized 
laboratory methods as described earlier (Thomas 1992, Fridewald et al. 1972). 
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Pathological tissue examination 
The heart, liver, kidney, EDL and Sol organ weights were measured. In muscles we 
were looking for signs of myopathy, in the kidneys for signs of renal failure, and in the liver, 
we examined the fatty degeneration as a result of high blood cholesterol levels. 
Immediately after removal, the tissue samples were fixed in 8% buffered formalin 
(24 h) and embedded in paraffin wax (Shandon pathcenter, Thermo-Shandon, USA). 4 µm 
sections were cut from paraffin embedded tissue samples and Haematoxillyn-Eosin (H&E) 
staining was performed. The samples were investigated with a LEICA DM 2500 microscope 
equipped with a LEICA DFC 420 camera (Leica Microsystems, Germany). The images were 
acquired and the diameter of the muscle cross sections were measured using LEICA 
Application Suite (LAS) V3 software. 
 
Measurement of muscle force 
Muscle contractions were measured as described in our previous reports (Oddoux et 
al. 2009). In brief, fast and slow twitch muscles, EDL and Sol, were removed and placed 
horizontally in an experimental chamber continuously superfused (10 ml min-1) with Krebs’ 
solution (containing in mM, NaCl 135, KCl 5, CaCl2 2.5, MgSO4 1, Hepes 10, glucose 10, 
NaHCO3 10; pH 7.2; room temperature, 23 oC) equilibrated with 95% O2 plus 5% CO2. One 
end of the muscle was attached to a rod while the other to a capacitive mechanoelectric force 
transducer. Two platinum electrodes placed adjacent to the muscle were used to deliver short, 
supramaximal pulses of 2 ms in duration to elicit single twitches. Force responses were 
digitized at 2 kHz by using Digidata 1200 A/D card and stored with Axotape software (Axon 
Instruments, Foster City, CA, USA). Muscles were then stretched by adjusting the position of 
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the transducer to a length that produced the maximal force response and allowed to equilibrate 
for 60 min. 
Single pulses 2 s apart were used to elicit single twitches. At least 10 twitches were 
measured under these conditions from every muscle. The individual force transients within 
such a train varied by less than 3% in amplitude, thus the mean of the amplitude of all 
transients was used to characterize the given muscle. To elicit a tetanus, based on the 
observations of Ranatunga (1982), single pulses were applied with a frequency of 200 Hz for 
200 ms in case of EDL and with a frequency of 100 Hz for 300 ms in case of Sol. Duration of 
individual twitches and tetani were determined by calculating the time between the onset of 
the transient and the relaxation to 90% of maximal force. 
To test how muscles fatigue 150 tetani were applied 2 s apart (Oddoux et al. 2009). 
The degree of fatigue was expressed by normalizing the amplitude of each tetani to that of the 
first. 
 
Measurement of resting calcium levels 
Resting intracellular calcium concentration ([Ca2+]i) was measured both in isolated 
fibers of the treated adult animals and in primary cultured striated muscle cells. 
For the former, EDC was removed and placed into the above described Krebs’ 
solution. The isolation of adult skeletal muscle fibers followed a protocol described 
previously (Szappanos et al. 2004). In brief, muscle fibers were separated by 90 min 
enzymatic digestion at 37°C in a shaker water bath with type 2 collagenase (Sigma) 
containing solution. These fibers were loaded with 5 µM Fura-2 AM fluorescent calcium-
sensitive dye in the presence of 150 nM neostigmin in Krebs’ solution. After wash, the dye 
was excited at two different wavelengths, 340 nm and 380 nm, using a Deltascan apparatus 
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(Photon Technology International, Piscataway, NJ, USA). Emission was detected at 510 nm 
and data analysis was performed using a home-made program. 
Cells in primary culture were loaded with the same concentration of Fura-2 AM and 
the loading and measuring process was done exactly the same way as in the adult fibers. 
 
Examination of cell proliferation and differentiation 
Primary cultures of rat striated muscle cells were photographed at 24, 48, and 72 hours 
after seeding using a Canon EOS-300D (Canon Corp., Japan) digital single lens reflex camera 
mounted on an inverted microscope. Photos of 5 fields of view per day per culture were taken. 
Myogenic nuclei were marked manually and morphometric analysis was done on these 
images. Cell proliferation and differentiation were assessed using the number of nuclei per 
muscle cell. 
 
Statistical analysis 
Averages – data unless otherwise stated were pooled over the animals or cell cultures 
within the same group – are presented as mean ± standard error of the mean. Significance of 
the differences between control and treated animals was assessed using ZZZ. Cell culture data 
did not show normal distribution, so Mann-Whitney Rank Sum test was used in that case. 
Differences were regarded significant at p<0.05. 
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Results 
 
Organ examination 
Although during the autopsy of the rats a slight body weight variability was 
experienced, the organs were grossly undamaged (Table 1). In microscopic examination of 
the liver moderate fatty degeneration was found only in rats with high blood cholesterol levels 
(Fig. 1). We could not detect abnormalities of the cross-striation or any other kind of damage 
in skeletal muscle samples observed with light microscopy. However, fluctuations in the 
diameter of EDL muscle fibers were observed on statin treated animals (Fig. 2). We found a 
significant decrease in the average of cross sectional area of the fibers after statin treatment 
(from 1835±79 µm2 to 1448±44 µm2 in the C and S groups, n= 161 and 288, respectively; 
from 2065±82 µm2 to 1664±44 µm2 in the HC and HC+S groups, n= 116 and 226, 
respectively). Neither the cross sectional area of the fibers from the HC, nor from the TU 
group (1801±65 µm2, n = 128) was significantly different from those of the control. 
 
Blood tests 
Blood cholesterol, triglyceride, and CK levels of the control rats (Table 2) were in the 
normal range (Suckow et al. 2006, Yerroum et al. 1999). On the other hand, as a result of the 
diet a marked, slightly more then seven times rise (from 1.45 to 10.7) in the total cholesterol 
level was observed in HC rats (Table 2). In addition, the ratio of the two main lipoproteins 
became inverted, while control rats had close to 90% HDL and only 10% of the atherogenic 
LDL, HC rats had only about 40% of HDL and the main lipoprotein was the LDL, similar to 
humans. Although the statin treatment did not change these ratios, it decreased the 
triglyceride levels in line with earlier reports (Krause and Newton 1995). Most importantly 
though, while the diet with high cholesterol alone did not elevate the CK level of the rats, 
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statin therapy, in the rats with elevated blood cholesterol levels more doubled these values 
(Table 2), proving the presence of myopathy in the skeletal muscles of the statin treated rats. 
Note also that while statin treatment in animals with normal blood cholesterol also induced an 
elevation in blood CK levels, this increase was far less dramatic than that observed in the 
HC+S group. 
 
Effects of statin treatment in cell culture 
After 24 hours of culturing in a medium enhancing proliferation and not containing 
fluvastatin all cultures reached almost complete confluence (Fig. 3a, d). In the differentiating 
medium that contained no fluvastatin further 24 hours were enough for muscle cells to fuse 
and take the spindle shape (Fig. 3b). The apparent decrease in cell count is due to the increase 
in the number of multinuclear cells. After further 24 hours (72 hours altogether) complete 
confluence was reached, cells were growing in multiple layers and large myotubes (cells with 
10+ nuclei) were present (Fig. 3c). In cultures, where the differentiating medium contained 
10 nM fluvastatin the number of spindle-shaped muscle cells clearly dropped by the 48th hour 
(Fig. 3e). The situation did not visibly improve after further 24 hours of culturing. In contrast 
to the control group, myotubes were practically absent in the fluvastatin-treated group (Fig. 
3f). 
Detailed morphometric analysis of the images confirmed the findings based on the 
visual inspection of the cultures. In the control group the number of myogenic nuclei 
increased, as compared to the end of the 1st culturing day, by 58% after 24 hours and by 
further 54% after an additional day. In contrast, the number of myogenic nuclei in the 
fluvastatin-treated group rose by only 3% after 24 hours and fell by 18% (decrease not 
significant) after another 24 hours. The differences in the relative number of nuclei between 
the control and the statin-treated groups were significant on both days 2 and 3 (Fig. 4a). 
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The fusion index showing the percentage of nuclei in multinuclear cells compared to 
all nuclei showed constant increase in both groups. However, the fusion index was 
significantly lower on both day 2 (0.68 vs. 0.84) and day 3 (0.81 vs. 0.91) in the fluvastatin-
treated group than in the control group, respectively (Fig. 4b). The median number of nuclei 
per cell was also significantly decreased by the statin treatment both after 48 hours (1 vs. 2; 
statin vs. control, respectively) and 72 hours (1 vs. 3; statin vs. control, respectively) of 
culturing. These data attest that more than 50% of muscle cells were mononuclear after 72 
hours of culturing in the statin-treated group. The decrease in the median cell size is apparent 
in the left shift of the histogram depicting data from day 3 (Fig. 4c). 
 
Resting Ca2+ concentration 
In cultured skeletal muscle cells resting [Ca2+]i was significantly decreased after statin 
treatment both in satellite cells and in myotubes (Fig. 5a). In the latter we found a more than 
40 nM decrease in the average value (119.4±4.5 nM vs. 72.3±2.8 nM; control vs. statin, 
respectively). The satellite cells of control cultures had essentially the same resting [Ca2+]i as 
the myotubes did (118.9±3.9 nM), while in the statin treated cultures the resting intracellular 
calcium concentration in the satellite cells was 98.7±6.2 nM. 
In contrast, chronic statin treatment in adult animals elevated the resting intracellular 
calcium level of isolated skeletal muscle fibers (Fig. 5b), independent of the cholesterol levels 
(85.9±1.1 nM vs. 91.3±1.1 nM; in C vs. S groups, respectively, and 116.1±3.8 nM vs. 
150.5±4.6 nM; in HC vs. HC+S groups, respectively). TU treatment alone slightly decreased 
these values (75.3±0.7 nM). It is important to stress that although the statin treatment did 
increase resting [Ca2+]i in animals with normal blood cholesterol, the elevation was much 
more pronounced in hypercholesterinaemic animals. 
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Muscle force 
Figure 6 presents individual traces of twitches (Fig. 6A and B) and tetani (Fig. 6C and 
D) from both EDL and soleus muscle of TU, HC and HC+S animals. As depicted in Fig. 6 
both single twitches and tetani were smaller in amplitude in HC+S than in TU and HC rats. 
Pooled data for the amplitudes of twitches and tetani are presented in Figure 7A and B, 
respectively. These reveal significant reduction in twitch force and in maximal force obtained 
during tetani for both muscle types in HC+S muscles compared to HC. This difference was, 
however, not present between muscles from animals of the TU and HC groups. 
It is important to note here that the cross sectional area of fibers from statin treated 
animals with high blood cholesterol was smaller than those with similar blood cholesterol but 
without statin therapy (see above). Force in was thus normalized to cross sectional area and 
pooled data for HC and HC+S groups were compared. Neither for EDL (17.6±3.1 vs. 
17.2±3.3 mN/mm2, twitches; 31.5±5.8 vs. 34.5±7.8 mN/mm2, tetani; HC and HC+S animals, 
respectively) nor for Sol (7.7±0.7 vs. 7.0±0.7 mN/mm2, twitches; 22.5±2.4 vs. 
20.2±4.5 mN/mm2, tetani; HC and HC+S animals, respectively) did normalized values differ 
significantly between the groups. These results indicate that loss of muscle tissue rather than 
significant alterations in maximal force of individual fibers was responsible for the decreased 
force presented in Figs. 6 and 7. 
The time course of the transients in Fig. 6 suggests an effect of chronic statin treatment 
on the kinetics of force production. Fig. 8 thus presents pooled data for the time-to-peak 
(TTP) and duration of twitches and tetani from both EDL and Sol. Although there were slight 
variations in TTP values in both EDL and Sol (Fig. 8A and B, respectively) due to the 
different conditions, these differences did not prove to be significantly significant. On the 
other hand, the duration of both twitches and tetani in soleus muscles (Fig. 8D) was 
significantly (p<0.05 ZZZ, respectively) shorter for the animals which received statin 
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treatment (HC+S group) than for the animals with high blood cholesterol level (HC group). 
Similar alterations in the duration of twitches and tetani for EDL – albeit present in tendency 
(Fig. 8C) – were not statistically significant. 
To test how muscles endure fatigue, series of tetani were applied. The ratio of the 
maximal force at the end of the test and initial tetanus did not show significant reduction in 
EDL muscles (0.63±0.03, 0.72±0.03, and 0.76±0.05 in muscles from TU, HC, and HC+S 
animals, n= 5, 6, 8, respectively). On the other hand, soleus muscles showed significantly 
greater fatigue in HC+S than in either TU or HC animals (0.79±0.05, 0.80±0.03, and 
0.64±0.06 in TU, HC, and HC+S muscles, n= 7, 6, 9, respectively). 
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Discussion 
Here we report of an animal model in which the administration of cholesterol together 
with cholic acid and thiouracyl in the diet resulted in a significant elevation of the blood 
cholesterol levels. In these animals the subsequent chronic administration of fluvastatin 
resulted in a clear myopathy described by a reduction in fiber cross sectional area and in 
muscle force. Not only was peak twitch and tetanic force reduced in both fast – m. EDL – and 
in slow – m. soleus – muscles, their duration in m. soleus was also decreased. In addition, 
resting [Ca2+]i was elevated in muscle fibers isolated from animals with high blood 
cholesterol and treated with statins. It should be noted that chronic statin treatment alone, that 
is in animals kept on normal rodent chow and having normal blood cholesterol, did not 
produce these effects. On the other hand, the presence of fluvastatin in the culture medium 
reduced the proliferation and prolonged the differentiation process of cultured myocytes. 
It is important to stress that we used artificially hypothyroid animals to further elevate 
blood cholesterol levels. This hypothyroid status of the animals with high blood cholesterol 
already resulted in an altered muscle function, and – combined with statin therapy – it 
manifested in a marked myopathy. To exclude the possibility that the reduction in muscle 
force was due to the hypothyroidism – caused by the thiouracyl in the diet – alone, animals 
kept on a thiouracyl diet were used as reference. Our results clearly demonstrated that the 
severe muscle problems were associated with the administration of fluvastatin and not with 
the hypothyroid state of the animals. 
Alterations in the calcium homeostasis were also suggested to play an important role 
in the pathophysiology of statin-induced myopathy (e.g. Sacher et al. 2005). A structural 
weakness in the T-tubular system, as T-tubules are more vulnerable to cholesterol depletion 
than other parts of the sarcolemma or the sarcoplasmic reticulum, of statin-treated patients has 
been demonstrated (Draeger et al. 2006). Furthermore, altered Ca2+ spark activity has been 
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reported following the acute treatment of muscle fibers by simvastatin (Sirvent et al. 2005). In 
addition, ryanodine receptor type 3 (RyR3) has been shown to be up-regulated in patients 
with statin-associated myopathy (Draeger et al. 2010). Since RyR3 is more sensitive to 
activating Ca2+, its overexpression in striated muscle is accompanied an increase in resting 
[Ca2+]i (Legrand et al. 2008). In line with the above, we observed a distinct elevation in the 
resting cytosolic levels of Ca2+ in muscle fibers following chronic statin treatment in this 
study. 
The cause of statin-associated myopathy is not yet clear, although there are some 
pharmacological properties, which have been characterized. Statin-induced muscle symptoms 
are dose-dependent and seem to be present for every molecule in the drug family. The risk 
factors are reported to be the old age, renal or hepatic impairment, concomitant use of 
fibrates, and co-administered drugs that either metabolize in the liver on the same cytochrome 
P450 (CYP) enzyme, or inhibit the CYP enzyme (CYP2C9 for fluvastatin, CYP3A4 for other 
statins; e.g. macrolide antibiotics, antifungal medications, gemfibrozil, cyclosporine, and 
grapefruit juice). These latter drugs can increase the serum concentration of statins, leading to 
higher risk of myopathy. These explain why several studies (e.g. Obata et al. 2009) as well as 
ours used higher statin doses than that present in therapy. 
The statin-associated myopathy is reported to be more common (9-20% of statin users) 
than indicated in the clinical studies (1-5%), and often leads to stop the drug taking (50% after 
1 year of treatment), thus these patients loose the potential beneficial effects of statin therapy 
on the blood cholesterol, cardiovascular morbidity and mortality (Buettner and Lecker 2008). 
Even in patients without myopathic complaints, statin therapy induced ultrastructural skeletal 
muscle damage (Draeger et al. 2006). 
Many potential mechanisms underlying the statin induced myopathy that have been 
reported in the literature (see e.g. Sirvent et al. 2008) could explain the alterations – modified 
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resting [Ca2+]i, reduced muscle force, hindered differentiation of myotubes – seen in this 
study. These include decreased cholesterol production leading to cholesterol depletion in the 
myocyte membranes (Harper and Jacobson 2007), and blocked HMG-CoA reductase activity 
resulting in decreased prenylation and thus altered function of small GTP-ases (Wang et al. 
2007). Normal cholesterol levels in phospholipids bilayers seem important in reducing Na+ 
leakage through these membranes and, therefore, lowering the energy expenditure of the Na+-
K+-pump and thus preventing ATP depletion of the cell (Haines 2001). Reduced amounts of 
cholesterol in the surface membrane would then lead to ATP depletion and, therefore, altered 
calcium homeostasis. Statins have also been reported to induce mitochondrial dysfunction 
(Sirvent et al. 2005), and/or Coenzyme Q10 deficiency, which can also lead to myopathy 
(Harper and Jacobson 2007, Ghirlanda et al. 1993) since these mechanisms tend to activate 
the apoptotic cascade (Dirks and Jones 2006, Kaufmann et al. 2006, Kohro and Yamazaki 
2009). Furthermore, changes in the ubiquitin-proteasome pathway have been referred to be 
associated with statin-induced myopathy as well (Buettner and Lecker 2008). 
Hypothyroidism or inherited mitochondrial dysfunction alone may lead to myopathy, 
thus worsen the side effect of statins. It should also be noted that statin treatment in control 
animals (group C) resulted in changes in the same direction albeit the changes were smaller 
(Buettner and Lecker 2008). Nevertheless, hypothyroidism does seem to play an important 
part in the statin-associated myopathy. In a case report, an asymptomatic hypothyroid patient 
received statin therapy and observed lower extremity myalgia within 4 weeks of treatment, 
which resolved ceasing the statin therapy (Bar et al. 2007). Another, more serious case was 
reported revealing a chronic, high dose grapefruit juice consumption triggered statin-
associated rhabdomyolysis with a CK elevated to 12640 U/l. The patient observed bilateral 
proximal leg weakness (Dreier and Endres 2004). 
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In line with the above mentioned observations we found a clear reduction in muscle 
strength and signs of muscle wasting in our animals with high blood cholesterol, thus treated 
with thiouracyl, following chronic statin administration. These animals not only had increased 
levels of plasma CK but displayed reduced twitch and tetanic force. In addition, we found a 
reduced ability of cultured myoblasts to differentiate, fuse and form multinucleated myotubes 
suggesting that the damaged muscle would also have an impaired repair mechanism. Our 
results thus raise the possibility that a hypothyroid status in hypercholesterolaemia increases 
the incidence of severe rhabdomyolysis if chronic statin treatment is applied. Furthermore, the 
animal model presented here should serve as a useful tool in studies on statin-induced 
myopathies. 
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Figure legends 
Figure 1. Intact liver tissue structure observed with light microscope (C, S, HC+S, TU). 
Moderate (small & large droplets, marked with arrows in the inset) fatty deposition seen in 
hypercholesterolaemic (HC) rats. H&E staining at 20x magnification. 
Figure 2. Pathologic structural changes cannot be seen on the cross-section of EDL muscle 
fibers under light microscope at any sample. However, fluctuation of the diameter of EDL 
muscle fibers can be observed on the statin treated samples. H&E staining at 40x 
magnification. 
Figure 3. Representative images of control (A-C) and statin-treated (D-F) rat primary skeletal 
muscle cell cultures. Fluvastatin (10 nM) was applied after the 24th hour of culturing. Arrows 
on panel C denote large myotubules with more than 10 nuclei. 
Figure 4. Detailed morphometric data of the effect of fluvastatin treatment on the 
proliferation and differentiation of cultured skeletal muscle cells. (A) Relative number of 
myogenic nuclei compared to the data at the 24th hour (the beginning of drug treatment in 
group S). (B) Fusion index showing the ratio of myogenic nuclei in multinuclear cells 
compared to all myogenic nuclei. (C) Histogram showing the distribution of cell size 
expressed as the number of nuclei in the cell. Error bars represent SEM. Asterisks denote 
significant difference between C and S treated cell cultures (p<0.05). 
Figure 5. (A) Resting Ca2+ concentration of satellite cells and myotubes in primary rat 
skeletal muscle culture. In control cultures satellite cells N=37, myotubes N=43. In statin 
treated cultures satellite cells N=13, myotubes N=12. (B) Resting Ca2+ concentration of the 
isolated myofibers of rats kept on different diets. Numbers in each column represent number 
of myofibers. Error bars represent SEM. Asterisks denote significant difference from C, # 
from TU and & from HC rats, (p<0.05). 
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Figure 6. Force transients in isolated muscles of TU, HC and HC+S rats. (A - B) Single 
twitches elicited by short (2 ms), supramaximal (5 V) stimulation on EDL (A) and Soleus (B) 
from TU (dotted), HC (dashed line) and HC+S (continuous line) rats. (C – D) Tetani elicited 
by a train of supramaximal stimulation at 200 Hz for 200 ms on EDL (C) and at 100 Hz for 
300 ms on soleus muscle (D) from TU (dotted), HC (dashed line), and HC+S (continuous 
line) rats. Measurements were made at 23 oC. 
Figure 7. Average twitch and maximal force. Data were pooled from 5 TU, 6 HC, and 10 
HC+S rats, after averaging the maximum of the force transients over each individual record 
(usually 10) measured on an individual muscle. Average amplitude of the twitches (A) and of 
the tetani (B). Asterisks denote significant difference between HC and HC+S rats (p<0.05). 
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Table 1. Average of the body weight and the weights of different organs in control and statin 
treated rats. 
Animal 
Group 
Body weight 
(g) 
Heart 
(mg) 
m. EDL 
(mg) 
m. soleus 
(mg) 
C (22) 127.3±20.6 527±34 76±3 91±7 
TU (10) 134.1±8.6 354±21 57±3* 72±3* 
HC (14) 119.3±2.1# 356±27 51±3 68±3 
HC+S (20) 132.3±3.6$ 358±36 55±4 74±7 
Number in brackets represents the number of animals. * denotes significant difference from C, 
#
 denotes significant difference from TU and $ denotes significant difference from HC. Note 
that since HC and HC+S animals have thiouracyl in their diet comparison in these cases were 
only made to the TU group. 
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Table 2. The average level of total cholesterol, triglyceride, the creatine kinase and the ratio 
of HDL and LDL cholesterol in the blood of the rats. 
Animal group 
 
Cholesterol 
(mmol/L) 
Triglyceride 
(mmol/L) 
Creatine Kinase 
(U/L) 
HDL/LDL 
 
C (15) 1.52±0.05 0.74±0.08 636.3±139.2 9.95±1.79 
S (10) 1.58±0.10 0.56±0.06 959.6±361.0 6.57±0.94 
TU (9) 1.45±0.08 0.35±0.04* 563.9±136.4 3.44±0.59* 
HC (16) 10.74±20# 0.53±0.06# 576.3±149.2 0.64±0.07# 
HC+S (12) 6.81±1.69# 0.46±0.06 1513.4±410.3#$ 0.94±0.22# 
Numbers in brackets represent the number of animals. * denotes significant difference from C, 
#
 denotes significant difference from TU and $ denotes significant difference from HC. Note 
that since HC and HC+S animals have thiouracyl in their diet comparison in these cases were 
only made to the TU group. 
